Payment overview · 2025
General Payments
$502.45
26 reported records · 10 companies
Healthcare provider profile · identity verified
Jaime E Trujillo, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · WINSTON SALEM, NC · NPI 1073564399
Verified facts
What the public records show
CMS Open Payments records show Jaime E Trujillo, MD received $502.45 in general payments during 2025 across 26 reported records.
Amgen Inc. accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $153.37 | 30.5% | 9 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $76.46 | 15.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.38 | 14.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.39 | 11.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.94 | 7.3% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $24.86 | 5.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.35 | 4.8% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $23.12 | 4.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.90 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.68 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $502.45 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $76.46 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $58.39 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.10 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.37 | 3 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $39.90 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.24 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 205 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
97 | 30 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
26 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
325 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
205 | 83 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 678 | 239 |
| Losartan Potassium | Losartan Potassium | 349 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 143 |
| Metformin Hcl | Metformin Hcl | 327 | 156 |
| Mounjaro | Tirzepatide | 325 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 293 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 206 | 84 |
| Ozempic | Semaglutide | 205 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 86 |
| Lisinopril | Lisinopril | 194 | 97 |
| Alendronate Sodium | Alendronate Sodium | 178 | 70 |
| Omeprazole | Omeprazole | 177 | 84 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 77 |
| Gabapentin | Gabapentin | 171 | 88 |
| Simvastatin | Simvastatin | 146 | 59 |
| Furosemide | Furosemide | 142 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 63 |
| Glimepiride | Glimepiride | 128 | 71 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 54 |
| Methimazole | Methimazole | 116 | 43 |
| Atenolol | Atenolol | 111 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 57 |
| Trazodone Hcl | Trazodone Hcl | 104 | 56 |
| Synthroid | Levothyroxine Sodium | 97 | 30 |
| Farxiga | Dapagliflozin Propanediol | 90 | 37 |
| Jardiance | Empagliflozin | 85 | 36 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 83 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 34 |
| Testosterone Cypionate | Testosterone Cypionate | 82 | 43 |
| Metformin Hcl Er | Metformin Hcl | 81 | 41 |
| Lorazepam | Lorazepam | 78 | 30 |
| Montelukast Sodium | Montelukast Sodium | 78 | 39 |
| Sertraline Hcl | Sertraline Hcl | 78 | 40 |
| Carvedilol | Carvedilol | 74 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 35 |
| Alprazolam | Alprazolam | 62 | 24 |
| Allopurinol | Allopurinol | 59 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 25 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 54 | 15 |
| Clonidine Hcl | Clonidine Hcl | 52 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 25 |
| Potassium Chloride | Potassium Chloride | 52 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 36 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 46 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 35 |
| Glipizide | Glipizide | 43 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 20 |
| Prednisone | Prednisone | 39 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 35 |
| Eliquis | Apixaban | 38 | 14 |
| Ezetimibe | Ezetimibe | 38 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 15 |
| Armour Thyroid | Thyroid,pork | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 17 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 20 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 32 | 16 |
| Glipizide Er | Glipizide | 30 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | 11 |
| Fenofibrate | Fenofibrate | 29 | 12 |
| Novolog | Insulin Aspart | 28 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 14 |
| Clonazepam | Clonazepam | 26 | 14 |
| Prolia | Denosumab | 26 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Topiramate | Topiramate | 25 | 12 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Propylthiouracil | Propylthiouracil | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | 15 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | 11 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | 11 |
| Celecoxib | Celecoxib | 22 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | 13 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 20 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | 14 |
| Meloxicam | Meloxicam | 19 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Valsartan | Valsartan | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 16 |
| Cephalexin | Cephalexin | 16 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | 12 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | 13 |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $502.45 · 26 records | Amgen Inc. | ABRYSVO, COMIRNATY, CeQur Simplicity, Dexcom G6 Transmitter, ETERNA, EVENITY, JARDIANCE, OTEZLA, Omnipod, Ozempic, PREVNAR 20, REPATHA, TEPEZZA, TWIIST, VRAYLAR, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error